Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 23, 2015 5:38pm
124 Views
Post# 24129611

RE:RE:PINKS DOWN .1 RVX up 5

RE:RE:PINKS DOWN .1 RVX up 5Yes you posed the same question before. And the answer is the same since none of the Resverlogix events mentioned in the previous post have happened yet (Yale Club, GCFF, AGM, BETonMACE enrollment launch, orphan disease announcment).

Friday 9/25 we have the Yale Club Presentation in New York 12-2:30 p.m. ET
 
Saturday 9/26 we have the GCFF (Global Chinese Financial Forum) in Toronto with DM giving the keynote speech, slotted for 40 minutes beginning at 9:30 a.m. ET
 
Wednesday 9/30 we have the AGM in Calgary (9 a.m. MT)

At Rodman and Renshaw on 9/10, regarding the Orphan indication Don said "And of course, very soon, within a matter of a couple weeks, we will be announcing an orphan indication that we will be moving forward with with RVX-208. Our future orphan indications will be with follow-on molecules, however in this first one we have such an advantage time-wise by using 208, that it seems to make a lot of sense to do that." I consider his "couple of weeks" to be 14 days plus or minus a few days. So he has a few more days for holding true to this one. I'd say if Monday rolls by without hearing anything then we have cause to gripe.

At Rodman and Renshaw on 9/10, regarding BETonMACE Don said "We’re actually within a very short few weeks from starting enrollment. So we will announce that when we do. We’re getting very close; it’s getting quite exciting." It hasn't been a few weeks yet (I think of a few as 3 or more).

Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#mZ5Ll7Kv8j8zDU9V.99
Bullboard Posts